Article

Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility

Bioinformatics and Biostatistics Unit, and Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, L'Hospitalet, Barcelona, Spain.
BMC Genomics (Impact Factor: 4.04). 02/2008; 9:12. DOI: 10.1186/1471-2164-9-12
Source: PubMed

ABSTRACT Germline genetic variation is associated with the differential expression of many human genes. The phenotypic effects of this type of variation may be important when considering susceptibility to common genetic diseases. Three regions at 8q24 have recently been identified to independently confer risk of prostate cancer. Variation at 8q24 has also recently been associated with risk of breast and colorectal cancer. However, none of the risk variants map at or relatively close to known genes, with c-MYC mapping a few hundred kilobases distally.
This study identifies cis-regulators of germline c-MYC expression in immortalized lymphocytes of HapMap individuals. Quantitative analysis of c-MYC expression in normal prostate tissues suggests an association between overexpression and variants in Region 1 of prostate cancer risk. Somatic c-MYC overexpression correlates with prostate cancer progression and more aggressive tumor forms, which was also a pathological variable associated with Region 1. Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6. Analysis of MYC/Myc-driven cell transformation and tumorigenesis substantiates a model in which MYC overexpression promotes transformation by down-regulating KLF6. In this model, a feedback loop through E-cadherin down-regulation causes further transactivation of c-MYC.
This study proposes that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline c-MYC expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor KLF6 gene.

Download full-text

Full-text

Available from: Xavier Solé, Jun 19, 2015
0 Followers
 · 
167 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although discovering proteomic biomarker by using mass spectrometry technique is promising, its rate of introducing proteomic biomarker approved by the US Food and Drug Administration is falling every year and nearly 1 per year on an average since 1998. Apparently, there is a big gap between biomarker discovery and biomarker validation. Here, we reviewed the challenges appearing in the three key stages for the pipeline of proteomic biomarker, that is, blood sample preparation, bioinformatics algorithms for biomarker candidate discovery, and validation and clinical application of proteomic biomarkers. To analyze and explain the reasons for the gap between biomarker discovery and validation, we covered areas ranging from the techniques/methods used in biomarker discovery and their related biological backgrounds to the existing problems in these techniques/methods.
    09/2009: pages 273-299;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In microarray genomics expression data obtained from hybridization of different cancer tissue samples or samples from cancer and normal cellular conditions, it is of interest to identify differentially expressed genes for follow-up validation studies. One approach to the analysis of genomics expression data is to first reduce the dimensionality using partial least squares (PLS), which has been useful in various cancer microarray data applications (Nguyen and Rocke, Bioinformatics 18:39–50, 2002a). PLS involves reducing the dimensionality of the gene expression data matrix by taking linear combinations of the genes/predictors (referred to as PLS components). However, the weights assigned to each gene and at each dimension are nonlinear functions of both the genes and outcome/response variable, making analytical studies difficult. In this paper, we propose a new measure for identifying relevant genes based on PLS weights called random augmented variance influence on projection (RA-VIP). We compare the relative performance of RA-VIP in terms of its sensitivity and specificity for identifying truly informative (differentially expressed) genes to two previously suggested heuristic measures, both based on PLS weights, namely the variable influence on the projection (VIP) and the PLS regression B-coefficient (denoted B-PLS). The methods are compared using simulation studies. We further illustrate the proposed RA-VIP measure on two microarray cancer genomics data sets involving acute leukemia samples and colon cancer and normal tissues.
    09/2009: pages 1-17;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Systems biology focuses on the study of interacting components of biological systems rather than on the analysis of single genes or proteins and offers a new approach to understand complex disease mechanisms by the use of computational models. The analysis of such models has become crucial to understand biological processes and their dysfunctions with respect to human diseases. A systems biology approach would be a key step in improving diagnosis and therapy of complex diseases such as cancer. It offers new perspectives for drug development, for example, in detecting drug side effects and alternative response mechanisms through the analysis of large cellular networks in silico. In this chapter we review important cellular processes for cancer onset, progression, and response to anticancer drugs, provide a summary of existing pathway databases and tools for the construction and analysis of computational models, and discuss existing kinetic models for cancer-related signaling pathways.
    09/2009: pages 227-242;